التاريخ:	--/--/-- --:--:--
مُعرِّف الحدث:	E5KSF3P6O
نوع الإجراء:	ACQUISITION
حالة الإجراء:	COMPLETED
رمز سهم الشركة المستحوِذة:
الرمز المُستهدَف:	ACLX
مُحدَّث:	--/--/-- --:--:--
سعر شراء السهم:	115
عملة سعر السهم الواحد:	USD
مصادر الأخبار:	https://www.businesswire.com/news/home/20260427408690/en/

ملاحظات حول الإجراء

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases.The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions.